Telo Genomics Technology to Detect & Profile Multiple Myeloma MRD (TELO - DMRD)

S

Sir Mortimer B. Davis - Jewish General Hospital

Status

Not yet enrolling

Conditions

Multiple Myeloma

Treatments

Diagnostic Test: Standard of care

Study type

Observational

Funder types

Other

Identifiers

NCT05530096
Telo Genomics Study

Details and patient eligibility

About

The purpose : Detect and profile Multiple myeloma Measurable Residual Disease(MRD) prognostics for monitoring post-transplant Multiple Myeloma (MM) Patients receiving maintenance therapy.

Enrollment

70 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Confirmed MM diagnosis
  • Transplant eligible patients in a first remission
  • Known MRD level detected by ClonoSeq (other IMWG recognized methodologies can be also employed)
  • Availability of deidentified patient's demographic and clinical follow up data
  • Receiving standard of care treatment
  • Able to provide informed consent

Exclusion criteria

Failure to meet inclusion criteria

Trial design

70 participants in 1 patient group

MRD level group
Description:
Participants will be defined as diagnosed with multiple myeloma
Treatment:
Diagnostic Test: Standard of care

Trial contacts and locations

0

Loading...

Central trial contact

Rayan Kaedbey, MD FRCPC

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems